Hong-Hu
0000-0003-2343-0436
8 papers found
Refreshing results…
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease
Venetoclax plus ‘2 + 5’ modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single‐centre retrospective analysis
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia
hCINAP regulates the DNA-damage response and mediates the resistance of acute myelocytic leukemia cells to therapy
CAG Regimen for Refractory or Relapsed Adult T-Cell Acute Lymphoblastic Leukemia: A Retrospective, Multicenter, Cohort Study
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia
Missing publications? Search for publications with a matching author name.